Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Oil Reservoir Analy

21 Jul 2008 07:00

RNS Number : 4429Z
ViaLogy PLC
21 July 2008
 



VIALOGY SHOWS EARLY SUCCESS IN OIL RESERVOIR ANALYSIS

London, July 21, 2008. ViaLogy PLC (LSE: VIY), announces completion of the initial phase of its pilot project with Atascosa Exploration LLC ("Atascosa") to apply its QuantumRD™ technology for geoseismic applications to determine the location and characteristics of underground oil deposits. 

With reference to a prospective Texas drilling site, the QuantumRD analysis confirmed the location of an oil trap, and mapped its size, shape, and predicted porosity. Atascosa estimates that this finding will save them over $500,000 by relocating the drill site to an optimal location some 700 feet from the site originally planned. In addition, ViaLogy's analysis discovered a second, deeper gas and oil trap of at least equal size. Work to drill both wells will begin in the coming weeks.

"We are very encouraged by ViaLogy's report, although final confirmation must await the results of drilling," said Atascosa CEO, John D. Mullins. "Our production engineering and geophysicist team is particularly impressed by the analysis tools Vialogy brings to bear in its novel approach to accurately characterizing reservoir prospects using existing datasets. We will look to grow our strategic collaboration with ViaLogy in analytical facets of reservoir modeling, water injection planning and enhanced recovery."

"The discovery of the new reservoir is remarkable, and could prove a significant find."

Atascosa confirmed that as payment for its QuantumRD work Vialogy is to receive a no-cost 5% working interest (WI), subject to existing agreements, royalty interest (RI), and overriding royalty interests (ORRI) in the wells drilled for each sand after payout of lease costs, geology, engineering, drilling, and other operational expenses. At each well payout, Atascosa will execute and deliver assignments to Vialogy sufficient to vest Vialogy with ownership of its 5% WI in the initial well in each sand and its right to participate in additional wells on the same basis as the other owners and as covered by the Operating Agreement.

The company estimates that this could produce approximately $8 million for Vialogy over the life of the wells. ViaLogy President and CEO Robert W. Dean stated; "We are very pleased to partner with Atascosa to commercialize our technology in the energy market. Atascosa's domain expertise will help us reach a broader problem and customer set. Geoseismology is an excellent vertical for us, as we will be able to realize a higher margin and performance premium for our disruptive technology. We are working with the Atascosa team to identify additional growth areas that we can address in the near-term."

For Further Information please contact:

ViaLogy Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656)

Nominated Advisor Seymour Pierce Mark Percy +44 (0) 20-7107-8000 

PR Consultants - Redleaf Communications  Emma Kane / Samantha Robbins +44 (0) 20-7822-0200 

About ViaLogy: Network Centric Signal Processing.

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFWFIASASEFW
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.